3200 Participants Needed

Questionnaire for Stomach Cancer

Recruiting at 6 trial locations
ML
XS
Overseen ByXiang Shu, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to gather health information to better understand and prevent gastric cancer by studying individuals with early signs of potential cancer development. Participants will include those with stomach conditions that could lead to cancer, such as gastric atrophy (thinning of the stomach lining), intestinal metaplasia (change in stomach lining cells), and dysplasia (abnormal cell growth). Healthy individuals and those with early-stage gastric cancer will also participate for comparison. This study suits individuals diagnosed with these stomach conditions or early gastric cancer who are not currently undergoing active cancer treatment.

As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could lead to improved prevention strategies for gastric cancer.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to gather comprehensive health information to better understand and prevent gastric cancer. Unlike existing treatments that focus on managing the disease after it develops, this study explores the early stages, such as atrophic gastritis and intestinal metaplasia, to identify patterns and factors that contribute to cancer progression. By analyzing data from both affected individuals and healthy controls, the study hopes to uncover insights that could lead to earlier detection and more effective prevention strategies. This proactive approach has the potential to transform how gastric cancer is tackled, shifting the focus from treatment to prevention.

Who Is on the Research Team?

ML

Monika Laszkowska, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I have early-stage stomach cancer and am having surgery at MSK.
I can read and understand English.
I have been diagnosed with a precancerous stomach condition.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Registry Creation

Participants with precursor lesions, gastric cancer, and healthy controls are enrolled to create a registry

Up to 10 years

Follow-up

Participants are monitored for progression of precursor lesions and comparison of baseline characteristics

Up to 10 years

What Are the Treatments Tested in This Trial?

Interventions

  • Questionnaire

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Participants with gastric cancerExperimental Treatment1 Intervention
Group II: Participants with atrophic gastritis, intestinal metaplasia, and dysplasiaExperimental Treatment1 Intervention
Group III: Control GroupExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+